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Abstract
The tetraspanin CD151 forms stoichiometric complexes with
laminin-binding integrins (e.g., α3β1, α6β1, and α6β4) and
regulates their ligand-binding and signaling functions. We
have found that high expression of CD151 in breast cancers
is associated with decreased overall survival (3.44-fold
higher risk of death). Five-year estimated survival rates
were 45.8% (95% confidence interval, 16.4-71.4%) for
CD151-positive patients and 79.9% (95% confidence interval,
62.2-90.0%) for CD151-negative patients. Furthermore,
CD151 was positively associated with axillary lymph node
involvement. To study the biological significance of this
observation, we investigated the contribution of CD151 in
breast cancer tumorigenesis using MDA-MB-231 cells as a
model system. Stable down-regulation of this tetraspanin
by short-hairpin RNA decreased the tumorigenicity of these
cells in mice. Detailed immunohistologic analysis of CD151
(+) and CD151(−) xenografts showed differences in tumor
vascular pattern. Vascularization observed at the
subcutaneous border of the CD151(+) tumors was less
pronounced or absent in the CD151(−) xenografts. In vitro
experiments have established that depletion of CD151 did
not affect the inherent proliferative capacity of breast cancer
cells in three-dimensional extracellular matrices, but
modified their responses to endothelial cells in coculture
experiments. The modulatory activity of CD151 was
dependent on its association with both α3β1 and α6β4
integrins. These data point to a new role of CD151 in
tumorigenesis, whereby it functions as an important
regulator of communication between tumor cells and
endothelial cells. These results also identify CD151 as a
potentially novel prognostic marker and target for therapy
in breast cancer. (Mol Cancer Res 2009;7(6):787–98)
Introduction
Transmembrane proteins of the tetraspanin superfamily are
the main structural unit of tetraspanin-enriched microdomains
that are implicated in various cellular functions including mo-
tility, differentiation, and cell-cell fusion (1-3). It has been pro-
posed that the functionality of the tetraspanin-enriched
microdomain relies on the associated transmembrane receptors
(e.g., adhesion molecules and receptor tyrosine kinases), the li-
gand binding and subsequent activities of which are influenced
by specific tetraspanins (2, 4).
Various tetraspanins are also linked to tumorigenesis as hav-
ing both protumorigenic and antitumorigenic activities. Over-
expression of CD9 and CD82/KAI1 suppressed proliferation,
tumorigenicity, and metastatic progression of various types of
tumor cells (5-9). These in vitro data have been supported by
observations of decreased expression of CD9 and CD82 in pa-
tients with advanced disease. The involvement of these tetra-
spanins in signaling and trafficking of the associated
receptors (e.g., integrins, EGFR) may, in part, explain their role
in tumor cell growth and metastatic spread (10, 11). In contrast,
CO-O29, the overexpression of which was observed in various
epithelial tumors, potentiates tumor cell growth in vivo by in-
ducing tumor angiogenesis (12). Proangiogenic function of
CO-029–expressing cells was linked to tumor-derived exo-
somes which stimulated angiogenesis both in vitro and in vivo.
These results indicate that tetraspanins can regulate various
steps (both for and against) in the tumorigenic process.
The tetraspanin CD151/PETA-3/SFA-1/Tspan24 forms high-
ly stable complexes with a number of integrins including α3β1.
Elevated expression of CD151 has been observed in patients
with advanced forms of non–small cell lung carcinomas and
prostate cancers (13, 14). Furthermore, previous reports have
shown that although CD151 did not influence tumor cell growth
at the primary site, it potentiated the metastatic properties of
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tumor cells (15, 16). These data are in agreement with numerous
in vitro experiments which identified CD151 as a promigratory
and proinvasive tetraspanin (16-22). It has been proposed that
CD151 regulates tumor cell invasion through mechanisms in-
volving associated integrins, receptor tyrosine kinase c-Met,
and matrix metalloproteinase-7 (23). More recently, it was found
that elevated expression of CD151 was observed in high-grade
and estrogen receptor (ER)–negative subtypes of breast cancers
(24). This was further correlated with the ability of CD151 to
facilitate the collaboration ofα6 integrins with epidermal growth
factor (EGF) receptor (EGFR; ref. 24).
In this article, we confirmed that elevated expression of
CD151 is observed in high-grade breast cancers. Furthermore,
for the first time, we showed that expression of this tetraspanin
was a significant negative prognostic indicator of overall sur-
vival in breast cancer. However, in contrast to a recent publica-
tion by Yang and colleagues (24), we found that there was no
correlation between the expression levels of CD151 and ER.
Using MDA-MB-231 breast cancer cells as a model system,
we have shown the contribution of CD151 to tumorigenesis
and found that CD151 regulates tumor cell responses to soluble
factors secreted by endothelial cells.
Results
Elevated Expression of CD151 Correlates with Lower
Survival of Patients with Breast Cancer
To examine the potential involvement of CD151 in breast can-
cer, we did immunohistochemical analyses on the archival speci-
mens from invasive ductal carcinoma. The median follow-up
period for 42 censored patients was 54 months (range, 9-63),
and for the whole group, it was 48.5 months (range, 1-63). During
follow-up, two deaths due to causes other than breast cancer were
observed. Patient characteristics are summarized in Supple-
mentary Table S1. Seventeen (30.4%) cases were identified im-
munohistochemically as being CD151-positive (Fig. 1A, top),
whereas 39 tumors were regarded as being CD151-negative
(Fig. 1A, bottom). Associations between clinicopathologic vari-
ables and overall survival are presented in Table 1. CD151-
positive patients had 3.44-fold higher risk of death from breast
cancer in comparison with CD151-negative patients. The 5-year
estimated survival rate was 45.8% [95% confidence interval
(CI), 16.4-71.4%] for CD151-positive patients and 79.9%
(95% CI, 62.2-90.0%) for the CD151-negative group (log rank
P = 0.016; Fig. 1B). Interestingly, additional analysis showed
that CD151 expression was positively associated with the in-
volvement of regional lymph nodes (P = 0.036). Importantly,
in contrast to a recently published report, we found no associa-
tion of CD151 expression with ER status (P = 0.640). In addi-
tion, no correlation with tumor grade (P = 0.810), disease stage
(P = 0.339), or age (P = 0.773) was observed. However, in a
group of 31 patients with metastases in regional lymph nodes,
CD151 expression showed a clear tendency towards worsening
of overall survival (hazard ratio of death, 2.89; 95% CI, 0.82-
10.19; P = 0.098).
Down-Regulation of CD151 Diminishes the Tumorigenic
Potential of Breast Cancer Cells
Histologic Analysis of CD151-Positive and CD151-Nega-
tive Xenografts. To assess the contribution of CD151 to the tu-
morigenic process, we did xenograft experiments using a pair
MDA-MB-231–derived cell lines which express high and low
levels of CD151 referred to as MDA-MB-231/CD151(+) and
MDA-MB-231/CD151(−) cells. The expression level of
CD151 in MDA-MB-231/CD151(−) cells was >90% lower
when compared with that of MDA-MB-231/CD151(+) cells
(25). The tumorigenicity of these cells was assessed following
xenotransplantation in athymic nude mice. As shown in Fig. 2A,
the growth of MDA-MB-231/CD151(−) cells was slower with
mean tumor sizes being ∼2-fold smaller by 21 days when com-
pared with MDA-MB-231/CD151(+) cells. Detailed histologic
analysis was carried out to compare patterns of tumor growth
in animals injected with CD151-positive and CD151-negative
MDA-MB-231 cells. Both CD151(+) and CD151(−) tumor
FIGURE 1. A. Positive (top) and negative (bottom) immunostaining for
CD151 in breast cancer specimens (magnification, ×200). B. Kaplan-
Meier estimate for overall survival in relation to CD151 expression.
CD151 expression is associated with poorer prognosis. Five-year overall
survival rate for CD151-positive patients was 79.9% as compared with
45.8% for CD151-negative patients (95% CI; hazard ratio, 3.44).
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nodules were composed of densely packed sheets of epithelioid
cells with pleomorphic nuclei, many containing prominent nu-
cleoli. In most CD151(+) tumors, there was central geographic
necrosis, hemorrhage with an associated inflammatory infiltrate.
At the subcutaneous margin of the CD151(+) xenografts, tumor
nodules were clearly demarcated from the epidermis by bands of
loose tissue composed of interwoven strands of fibrin, endothe-
lial and mesenchymal cells, and infiltrated by granulocytes and
lymphocytes (Fig. 2B and D). By contrast, CD151-negative xe-
nografted tumor cells infiltrated the dermis with no apparent
boundary between the tumor nodule and the epidermis
(Fig. 2B). There was also less subcutaneous inflammation and
intratumoral necrosis when compared with the CD151(+) tu-
mors. Prevalence of necrotic areas in CD151(+) xenografts
might have been due to the larger size of the tumors. The prolif-
erative capacity of MDA-MB-231/CD151(+) and MDA-MB-
231/CD151(−) cells in vivo was assessed by immunostaining
of xenograft sections with antibody to Ki-67, a widely accepted
marker of cell proliferation (26). The overall Ki-67 labeling in-
dex in CD151(−) xenografts was decreased when compared with
CD151(+) tumors (90.00 ± 3.267 versus 108.7 ± 6.005, respec-
tively; P = 0.0145; Fig. 2C).When specific regions of the tumors
were analyzed, the results showed that differences in cell prolif-
eration between CD151(+) and CD151(−) xenografts were most
pronounced at the deep border of the tumors: 154.8 ± 5.69 for
CD151-positive tumors versus 119.0 ± 5.080 for CD151-nega-
tive tumors (P < 0.0001).
To analyze the inflammatory response of the host and vas-
cularization of the xenografts, consecutive sections were immu-
nostained for F4/80, a marker of murine macrophages (27), and
Lycopersicon esculentum lectin, which reacts with murine en-
dothelium (28), respectively. In both MDA-MB-231/CD151(+)
and MDA-MB-231/CD151(−) xenografts, F4/80-expressing
cells were found scattered throughout the tumor with higher
numbers at the margin of the tumors. This gradient was more
pronounced in CD151(+) tumors (Fig. 3A). Although overall
quantitative assessment of vessel density did not show signifi-
cant difference between the two types of xenografts [CD151
(+), 5.37 ± 0.3150; CD151(−), 4.67 ± 0.199; P = 0.2977;
95% CI], vascularization of xenografts differed in the pattern
of vessel distribution. Specifically, an angiogenic network at
the subcutaneous border was better developed in CD151-
positive tumors (Fig. 3A and B). MDA-MB-231 cells are
known to secrete proangiogenic growth factors, vascular endo-
thelial growth factor (VEGF) and basic fibroblast growth fac-
tor, which contribute to the growth and vascularization of
xenografts in vivo (29, 30). However, we found that the control
and MDA-MB-231/CD151(−) cells produced similar amounts
of these proteins under standard culturing conditions, and there
was no difference in either intensity or distribution of VEGF
and basic fibroblast growth factor between the xenografts (Sup-
plementary Fig. S1). Furthermore, we found that morphogene-
sis of cultured human umbilical vascular endothelial cells
(HUVEC) on Matrigel was affected in equal measure by
growth medium conditioned with MDA-MB-231/CD151(+)
and MDA-MB-231/CD151(−) cells (Fig. 3C). These results
suggest that different patterns of angiogenesis of MDA-MB-
231/CD151(+) and MDA-MB-231/CD151(−) xenografts are
likely to be a result of differences in cooperation between grow-
ing tumor cells and the host microenvironment.
The Role of CD151 in the Growth of Breast Cancer Cells
in Three-dimensional Extracellular Matrix
As a first step towards understanding how CD151 can reg-
ulate tumor cell growth in vivo, we compared the behavior of
MDA-MB-231/CD151(+) and MDA-MB-231/CD151(−) cells
embedded in 0.16% collagen type I gels and Matrigel. Within
7 to 8 days after plating in collagen, both MDA-MB-231/
CD151(+) and MDA-MB-231/CD151(−) cells formed exten-
sive networks of cables/cords (Fig. 4A). Quantification of these
experiments has shown that depletion of CD151 had no observ-
able effect on length, thickness, or branching of the cables
formed in three-dimensional collagen (results are not shown).
When grown within three-dimensional Matrigel, both MDA-
MB-231/CD151(+) and MDA-MB-231/CD151(−) cells formed
compact colonies (Fig. 4B). Morphometric analysis of the col-
onies (i.e., colony diameter measurement) showed that a defi-
ciency in CD151 does not change the inherent proliferative
potential of MDA-MB-231 cells in three-dimensional extracel-
lular matrix (ECM; Fig. 4C). This was subsequently confirmed
when we measured the proliferation of MDA-MB-231/CD151
(+) and MDA-MB-231/CD151(−) cells in three-dimensional
Matrigel using Alamar blue (Fig. 4D).
CD151 Regulates the Responses of Tumor Cells to
Endothelial Cells but not Fibroblasts
We hypothesized that the inhibitory effect of CD151 deple-
tion on growth in vivo may be due to the involvement of this
tetraspanin in the communication between tumor cells and the
surrounding stromal cells. First, we examined whether the pres-
ence of fibroblasts originated from various tissues affecting the
growth of MDA-MB-231 cells in three-dimensional ECM. In
these experiments, MDA-MB-231 cells were seeded in three-
dimensional ECM over the monolayer of fibroblasts grown
on plastic. We found that there was no migration of fibroblasts
into three-dimensional ECM under these experimental condi-
tions. When compared with the control conditions (i.e., cultur-
ing alone), coculturing with fibroblasts potentiated the growth
of both CD151-positive and CD151-negative cells which de-
veloped more elaborate networks of cables in three-dimension-
al collagen within 7 to 8 days after plating (Fig. 5A). The
pattern of growth and various morphometric variables (e.g.,
Table 1. Associations between Clinicopathologic Variables
and Overall Survival
Variable Hazard Ratio (95% CI) P
Age (y)
<50 vs ≥50 1.59 (0.55-4.61) 0.389
Disease stage
III vs I-II 0.87 (0.27-2.77) 0.813
Grading
3 vs 1-2 1.29 (0.43-3.85) 0.652
Nodal status
Positive vs negative 3.53 (0.98-12.65) 0.053
ER status
Positive vs negative 0.14 (0.03-0.62) 0.001
CD151 status
Positive vs negative 3.44 (1.18-10.04) 0.024
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length and thickness of the cables) were comparable in MDA-
MB-231/CD151(+) and MDA-MB-231/CD151(−) cells. Simi-
larly, we observed no difference in growth in the presence of
fibroblasts when CD151-positive and CD151-depleted cells
were seeded into three-dimensional Matrigel (Fig. 5B). We then
examined whether coculturing with human endothelial cells
affects the growth of CD151-positive and CD151-depleted
MDA-MB-231 in three-dimensional Matrigel. In the presence
FIGURE 2. Down-regula-
tion of CD151 causes inhibi-
tion of tumor cell growth. A.
Tumo r g r ow t h i n m i ce .




CD151(−) cells in athymic
nude mice. Ten mice were
used in each group. Tumors
became measurable ∼8 to
10 d posttransplantation; this
is represented as day 0 on
the graph. Points, means of
tumor volumes evaluated at
various time intervals; bars,
SE. Presence of CD151 af-
fects the histology of MDA-
MB-231 xenografts. B. H&E
staining of MDA-MB-231 xe-
nografts. CD151(+) tumors
are clearly separated from
the epidermis by bands of
loose tissue composed of in-
terwoven strands of fibrin, en-
dothelial and mesenchymal
cells, and infiltrated by neutro-
phils (left; inset; magnifica-
tion, ×200) whereas CD151
(−) tumor cells infiltrate the
dermis with no apparent
boundary between the nodule
and the epidermis (right; in-
set; magnification, ×200). C.
Ki-67 labeling index. Results
of quantification of Ki-67–im-
munopositive cells (average
from nine high-power fields,
∼1,000 cells/sample; magnifi-
cation, ×400). D. Giemsa
staining of subcutaneous bor-
der MD-MB-231 xenografts.
Differentiation of nuclear mor-
phology of the cells reveals
rich infiltration composed of
lymphocytes (arrows) and
granulocytes (arrowheads) in
CD151(+) tumors (left) and al-
most absent from CD151(−)
tumors (right).
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of HUVEC, most of the MDA-MB-231/CD151(+) colonies
(∼65%) displayed a characteristic “scattering” phenotype (i.e.,
aggregates of loosely associated cells; Fig. 5C, left). By con-
trast, MDA-MB-231/CD151(−) cells were less responsive to
HUVEC with >80% of the colonies retaining a “compact” mor-
phology (Fig. 5C, right). In agreement with these findings, we
observed specific differences in signaling when MDA-MB-
231/CD151(+) and MDA-MB-231/CD151(−) cells were ex-
posed to the medium conditioned by HUVEC. First, activation
of extracellular signal-regulated kinase-1/2 (ERK1/2) was more
robust in CD151-positive cells (Fig. 5D, lanes 1-4; Fig. 5E).
Second, the dynamics of activation of Src kinases was also dif-
ferent. Whereas in MDA-MB-231/CD151(+) cells, the levels of
active Src kinases have increased with prolonged incubations,
the absence of CD151 reversed this trend (Fig. 5D, lanes 1-4).
Importantly, the levels of active ERK1/2 and Src kinases were
comparable when cells were plated on Matrigel in a standard
growth medium (i.e., DMEM/10% fetal bovine serum;
Fig. 5D, lanes 5-8). Furthermore, activation of PKB/c-Akt or
basal levels of phosphorylation of FAK and p130Cas were not
affected (Fig. 5D). To investigate whether such a selective effect
of CD151 depletion on Src and Erk1/2 activation correlated with
the behavior of MDA-MB-231 cells in three-dimensional
Matrigel, we examined cellular growth in the presence of a
specific Src (or MEK) inhibitor. In these experiments, we used
FIGURE 3. A. Subcutaneous zones of MDA-MB-231/CD151(+) (left)
and MDA-MB-231/CD151(−) (right) xenografts (magnification, ×100). Im-
munohistochemistry: distribution of macrophages (top) and endothelial
cells (bottom) was analyzed using monoclonal antibody F4/80 and biotiny-
lated L. esculentum (tomato) lectin, respectively. Note the gradient of im-
munoreactivity which is particularly clearly prominent in CD151(+)
xenografts. B. Vascularization of tumor xenografts. Analysis of vasculari-
zation was done as described in Materials and Methods. The numbers
represent the average from nine counts per tumor. C. The effect of
MDA-MB-231–conditioned medium (CM-MDA-MB-231) on endothelial
cells (HUVEC). HUVEC were plated on polymerized Matrigel for 24 h in
growth medium conditioned by MDA-MB-231/CD151(+) and MDA-MB-
231/CD151(−) cells for 4 d.
FIGURE 4. Contribution CD151 to growth in three-dimensional matrix.
A. Growth in three-dimensional collagen. Cells were embedded into colla-
gen gels as described in Materials and Methods and grown for 8 d. B to D.
Growth in three-dimensional Matrigel. Cells were embedded into growth
factor–reduced Matrigel as described in Materials and Methods and grown
for 10 d. Bars, 200 μm.C. Quantification of colony sizes. Colony diameters
were measured using ImageJ. The diameters of more than 50 colonies
were measured for each of the cell lines in each of three separate experi-
ments. Ratio of average colony diameter for CD151-positive and CD151-
depleted MDA-MB-231 was calculated for each experiment. Columns,
mean of ratios; bars, SD. D. Measurements of cell proliferation. Cell pro-
liferation was measured using Alamar blue by a spectrofluorometric meth-
od. Columns, mean of two experiments (each in triplicate); bars, SD (AFU,
arbitrary fluorescence units).
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HUVEC-conditioned medium (HUVEC-CM) to avoid the
potentially adverse effects of inhibitors on endothelial cells.
Figure 5F illustrates that inhibition of Src kinases attenuated
HUVEC-CM–induced growth and scattering of MDA-MB-
231/CD151(+): the number of colonies which displayed a scat-
tering phenotype decreased from ∼72% to ∼ 28%. On the other
hand, despite the fact that in the presence of MEK1/2 inhibitor,
UO126 growth of both CD151(+) and CD151(−) cells was im-
paired, no apparent effect on scattering of MDA-MB-231/
CD151(+) in three-dimensional Matrigel was observed (results
are not shown). These data strongly suggest that signaling via
Src kinases contributes to CD151-dependent scattering induced
by a HUVEC-produced soluble factor.
It has recently been reported that CD151 regulates cellular
responses to EGF (24). Thus, we examined the behavior of
MDA-MB-231/CD151(+) and MDA-MB-231/CD151(−) cells
grown in three-dimensional ECM in the presence of EGF. As
shown in Fig. 6A, the presence of EGF did not change the ap-
pearance or size of the colonies in three-dimensional Matrigel
when compared with the control conditions. Furthermore, we
observed no difference in EGF-induced or HB-EGF–induced
tyrosine phosphorylation of cellular proteins, or activation of
ERK1/2 and c-Akt (Fig. 6B). These results argue against the
involvement of EGFR in the CD151-dependent cellular re-
sponses to an endothelial-derived soluble factor(s).
Association with Integrins Is Critical for CD151-Mediated
Response of MDA-MB-231 Cells to HUVEC
To establish whether CD151-dependent sensitization to HU-
VEC involves integrins, we examined the responses of MDA-
MB-231/CD151(−) cells which were engineered to express
CD151-QRD mutant [MDA-MB-231/CD151(−)/rec/QRD
cells]. A previous study has shown that mutation of QRD to
INF (residues 194-196) within the large extracellular loop pre-
vents direct interactions between CD151 and integrins within
tetraspanin-enriched microdomains (31). We confirmed this
observation using MDA-MB-231/CD151(−)/rec/QRD cells
(25). As a control for these experiments, we used MDA-MB-
231/CD151(−) cells re-expressing the wild-type CD151
[MDA-MB-231/CD151(−)/rec/wt cells]. Western blotting anal-
ysis showed that the expression levels of CD151-QRD mutant
and wild-type protein in reconstituted cell lines were compara-
ble (25). As expected, MDA-MB-231/CD151(−)/rec/wt cells
regained their responsiveness to HUVEC (Fig. 7A, left) with
>75% of the colonies exhibiting a scattering phenotype in
three-dimensional Matrigel. On the contrary, the appearance
of MDA-MB-231/CD151(−)/rec/QRD colonies was similar to
that of the CD151-negative cells (Fig. 7A, right). In comple-
mentary experiments, we analyzed the contribution of integrins
α3β1 and α6β4, principal integrin partners of CD151 in
MDA-MB-231 cells, to HUVEC-induced cellular responses
in three-dimensional ECM. Towards this end, we established
stable MDA-MB-231 cell lines which expressed low levels
of these integrins (referred to as MDA-MB-231/α3β1low and
MDA-MB-231/α6β4low). Flow cytometry experiments have
shown that the levels of analyzed growth of α3β1 and α6β4
integrins were decreased by >90% (Fig. 7B). As illustrated in
Fig. 7C, both MDA-MB-231/α3β1low and MDA-MB-231/
α6β4low cells lost the ability to respond to the presence of en-
dothelial cells and formed compact colonies in three-dimen-
sional Matrigel. Taken together, these experiments show that
the association with both α3β1 and α6β4 is critical for the
CD151-dependent sensitization of tumor cells to soluble fac-
tors secreted by the endothelial cells.
Discussion
Our report identifies CD151 as an independent marker for
poor prognosis in invasive ductal carcinoma of the breast and
shows, for the first time, that increased expression of CD151 is
associated with decreased overall survival. Furthermore, our
xenograft experiments support the involvement of CD151 in
breast cancer tumorigenesis and point to a new role for
CD151 as a regulator of communication between tumor cells
and the endothelium.
Previous work from this and other laboratories has shown
that CD151 plays an important role in integrin-dependent inva-
sive migration of tumor cells (32-34). Furthermore, using spe-
cific anti-CD151 monoclonal antibody, Zijlstra and colleagues
found that CD151 may be involved in intravasation (15). How-
ever, this monoclonal antibody did not inhibit primary tumor
growth. Here, we show that CD151 also plays a positive role
in tumor cell growth in vivo. Interestingly, CD151 did not con-
tribute to the inherent proliferative potential of tumor cells
when they were grown in three-dimensional ECMs under stan-
dard culture conditions. These results suggest that increased
proliferation of CD151-positive xenografts is dependent on
host cells surrounding growing tumors. Indeed, we found that
a deficiency in CD151 attenuated the responses of MDA-MB-
231 to endothelial cells. We also showed that responses to a
soluble factor(s) produced by endothelial cells require interac-
tions between CD151 and integrins. This observation further
strengthens the notion that tetraspanins are involved in the as-
sembly of scaffolding platforms for lateral coordination of sig-
naling pathways between various transmembrane receptors (4).
As such, CD151 may link integrins with a receptor for the en-
dothelium-derived soluble factor.
MDA-MB-231 cells express three principal CD151 integrin
partners: α3β1, α6β1, and α6β4. Although it remains to be
established which of the CD151-integrin complexes contribute
FIGURE 5. Contribution of fibroblasts and endothelial cells to growth of MDA-MB-231 cells in three-dimensional ECM. Cells embedded in three-dimen-
sional collagen (A) or Matrigel (B and C) were grown above the monolayer of fibroblasts (A and B) or HUVEC (C) as described in the legend to Fig. 4. Bars,
100 μm (A) or 50 μm (B and C). D. The effect of CD151 depletion on signaling. Serum-starved cells were detached using EDTA and subsequently resus-
pended in standard growth medium (DMEM/fetal bovine serum) or growth medium conditioned by HUVEC (HUVEC-CM). The cells were plated on Matrigel
for the indicated time intervals and then scraped into Laemmli buffer. Proteins were resolved in 10% SDS-PAGE under reduced conditions. The proteins were
transferred to a nitrocellulose membrane and probed with the indicated polyclonal antibodies. E. Densitometric analysis of activation Erk1/2 (i.e., measure-
ments of pErk1/2) for the results in D. Measurements were done for two independent experiments (A.D.U., arbitrary densitometry units). Note, the ratios of
∼1.6 (for the 15-min time point) and ∼1.3 (for the 45-min time point) indicate that the presence of CD151 potentiates HUVEC-CM–induced activation of Erk1/2.
F. The effect of Src inhibitor on the growth of MDA-MB-231 cells in three-dimensional Matrigel. Cells were embedded in three-dimensional Matrigel and grown
for 8 d in HUVEC-CM supplemented with 2 μmol/L of SU6656. The medium was changed every second day. Bar, 50 μm.
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to the growth of MDA-MB-231 xenografts, it is likely that both
α3β1-CD151 and α6β4-CD151 complexes are involved. Pro-
tumorigenic activity of α6β4 in breast cancer has been shown
in various animal models (35-37), and this agrees with the ob-
servation that the elevated expression of this integrin is associ-
ated with significantly decreased overall survival of patients
with breast cancer (38, 39). Similarly, the increased levels of
α3β1 correlated with metastatic progression in breast cancer
(40). Although further studies will be necessary to establish
the clinical significance of this observation, we found that de-
pletion of α3β1 integrin significantly inhibited both the growth
of MDA-MB-231 cells in three-dimensional ECM in vitro and
in xenograft experiments.8
It has been recently proposed that CD151 functions as a
molecular linker between laminin-binding integrins (i.e.,
α3β1 and α6β1/4) and c-Met, a receptor for hepatocyte growth
factor (HGF; ref. 23). The functional link between c-Met and
integrins is also supported by the observation that HGF can
FIGURE 6. CD151-dependent cellular responses in three-dimensional
Matrigel does not involve EGFR. A. Cells were embedded into growth fac-
tor–reduced Matrigel as described in Materials and Methods, and grown in
the presence or absence of EGF (10 ng/mL) for 8 d. Bar, 200 μm. B. The
effect of CD151 depletion on signaling via EGFR. Serum-starved cells
were stimulated with EGF (50 ng/mL) or HB-EGF (50 ng/mL) for the indi-
cated time intervals and then scraped into Laemmli buffer. Proteins were
resolved in 10% SDS-PAGE under reduced conditions. The proteins were
transferred to a nitrocellulose membrane and probed with the indicated
polyclonal antibodies.
FIGURE 7. The role of integrins in CD151-dependent cellular re-
sponses to endothelial cells. A and C. Various derivatives of MDA-MB-
231 cells were plated in three-dimensional Matrigel and grown in the pres-
ence of HUVEC as described in Fig. 5. Bars, 50 μm. B. Generation of
stable α3β1-depleted and α6β4-depleted cells. Down-regulation of integ-
rins in MDA-MB-231 cells was analyzed by flow cytometry. Cells stained
with mouse monoclonal antibody against either α3 (A3-IVA5; left histo-
gram) or β4 (3E1; right histogram) integrin subunits.
8 R. Sadej, K. Gkirtzimanaki, A.G. Eliopoulos, F. Berditchevski, unpublished results.
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stimulate integrin avidity (41). However, it is unlikely that
CD151-dependent differential responses to HUVEC are caused
by deficiencies in the HGF → c-Met signaling axis in MDA-
MB-231/CD151(−) cells. First, HUVEC do not seem to
produce HGF (42). Second, the absence of CD151 did not af-
fect the growth pattern of breast cancer cells in three-dimen-
sional ECM in coculture experiments with dermal fibroblasts,
a rich source of HGF (43). Recently, Yang and colleagues sug-
gested that the protumorigenic function of CD151 may involve
signaling via EGFR (24). Our results clearly indicate that the
growth of MDA-MB-231/CD151(+) and MDA-MB-231/
CD151(−) cells in three-dimensional ECM is not affected by
the presence of EGF. Furthermore, we have thus far been un-
able to identify the difference(s) between CD151-positive and
CD151-negative MDA-MB-231 cells when we analyzed vari-
ous signaling pathways triggered by EGF. In a recent study, we
showed that invasiveness through Matrigel along the gradient
of EGF is controlled by the CD151-α3β1 complex (25). These
results, and the observation by Yang and colleagues, agree with
the concept that CD151 may be involved in the coordination of
signals via laminin-binding integrins and EGFR, and this is
likely to play an important role in tumor cell invasiveness
and metastasis. However, the results presented here argue
against the involvement of an EGFR-CD151-integrin sig-
naling axis in the growth of MDA-MB-231 cells in the animal
model. Identification of the relevant ligand-receptor pair and
dissection of signaling pathways leading to the activation of
ERK1/2 and Src kinases should clarify the role played by
CD151 in the transmission of the signal from endothelial cells
and shed light on the involvement of CD151 in tumor cell
growth in vivo.
Distinct patterns of vascularization observed in CD151-pos-
itive and CD151-negative xenografts may explain the subtle
differences in histologic appearance of the tumors and distribu-
tion of tumor-infiltrating macrophages. Furthermore, a more
pronounced effect on proliferation at the deep border of the tu-
mor (judged by the Ki-67 index) may suggest a less efficient
supply of endothelium-derived or macrophage-derived growth
factors to CD151(−) tumors. Conversely, the diminished
growth rate of CD151-negative cells may have a lower meta-
bolic demand, and consequently, induces less pronounced vas-
cularization of xenografts. Of interest, the protumorigenic
function of another tetraspanin (CO-029/Tspan8/D6.1A) in
pancreatic tumor cells was also associated with the paracrine
activity of the protein (12, 44). Induction of angiogenesis by
the Tspan8-expressing tumors seems to involve tumor-derived
exosomes and, in part, increased the production of VEGF and
matrix metalloproteinase-13 (12). Although culture medium
conditioned by MDA-MB-231 can also affect in vitro angio-
genesis (45), we found that the absence of CD151 did not in-
fluence the modulatory activity of the medium conditioned by
these cells. Although more studies are necessary to dissect a
complex circuitry of communication between tumor cells and
vasculature, our data indicate that CD151-dependent paracrine
activity of MDA-MB-231 is likely to require contributions
from other components of the tumor microenvironment (e.g.,
macrophages).
We have shown that elevated expression of CD151 inversely
correlates with overall survival of breast cancer patients with
invasive ductal carcinoma. More detailed analysis is necessary
to establish whether overexpression of CD151 is associated
with any of the five distinct subtypes of breast cancer (46).
In this regard, we did not observe a significant correlation be-
tween the overexpression of CD151 and ER and progesterone
receptor status in our invasive ductal breast adenocarcinoma
samples. These results are at odds with the report by Yang
and colleagues, who observed elevated expression of CD151
in 45% of ER-negative breast tumors. Although more work is
required to draw a definitive conclusion, we would like to em-
phasize that in contrast to the work by Yang and colleagues, our
analysis was done on a homogenous group of specimens (i.e.,
invasive ductal carcinomas).
In summary, we have shown that tetraspanin CD151 regu-
lates the growth of breast cancer cells in vivo by controlling
their communication with endothelial cells. Importantly, our
data link the overexpression of CD151 with lower survival of
patients with breast cancer, thereby identifying this tetraspanin
as an independent prognostic marker and potential novel target
for developing new therapies.
Materials and Methods
Cells, Antibodies, and Reagents
MDA-MB-231 cells were grown in DMEM (Sigma) supple-
mented with 10% fetal bovine serum. Fibroblasts were derived
from either the synovium or skin of patients with arthritis un-
dergoing joint replacement, and then isolated and cultured as
described (47). HUVEC (PromoCell) were grown in endotheli-
al cell growth medium with SupplementMix (PromoCell). The
mouse anti-CD151 monoclonal antibodies were 5C11 (48),
11B1G4 (provided by Dr. L. Ashman, University of Newcastle,
Australia), and NCL-CD151 (Novocastra). Rabbit polyclonal
anti-human Ki-67 antibody was from Abcam, rat anti-mouse
F4/80 antigen monoclonal antibody was from AbD Serotec,
rabbit anti-human FGF2 antibody was from Santa Cruz Bio-
technology, and mouse anti-human VEGF monoclonal anti-
body was from BD PharMingen. Anti-phosphorylated FAK
(Tyr397) antibody was purchased from BD Bioscience, and
anti–β-actin was from Sigma. The rest of the antibodies used
in this study were purchased from Cell Signaling Technology.
Biotinylated L. esculentum lectin (Vector Labs) was used to
identify mouse endothelial cells.
Construction of MDA-MB-231 Knockdown Cell Lines
Generation of MDA-MB-231/CD151(+), MDA-MB-231/
CD151(−), MDA-MB-231/CD151rec, and MDA-MB-231/
CD151-QRD stable cell lines were described earlier (25).
MDA-MB-231/α3β1low cells were established from MDA-
MB-231/CD151(+) by fluorescent sorting of the cells expressing
short-hairpin RNA (shRNA) that specifically targets the α3 in-
tegrin subunit (target sequence is 5′-gctacatgattcagcgcaa-3′).
MDA-MB-231/α6β4low cells were generated using a specific
shRNA construct which targets the β4 integrin subunit (35).
Assessment of Cell Growth in Three-dimensional ECM
Growth in Matrigel. Three drops of cell suspension in Ma-
trigel (∼1.5 × 103/40 μL) were plated onto a tissue culture plate
and incubated at 37°C for up to 30 min to solidify. Solidified
Matrigel drops were covered with growth medium. Colonies
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were photographed 10 d after plating. Relative size of the
colonies was determined by measuring 60 to 100 random col-
onies in each drop using ImageJ software. At least two inde-
pendent experiments were carried out for each cell line.
Growth in collagen. Cells were suspended in 1.6 mg/mL of
rat tail collagen type I (∼1.5 × 103/40 μL) and grown for 7 to
8 d. Colonies were analyzed using Zeiss Axiovert 25 micro-
scope. In coculture experiments, fibroblasts (or HUVEC) were
grown in 48-well plates until they reached ∼80% confluence.
Subsequently, MDA-MB-231 cells (∼8 × 103/200 μL) sus-
pended in collagen or Matrigel were overlaid and the cultures
continued to grow for an additional 7 to 10 d with growth me-
dium being replaced every 48 h.
Western Blotting
Growing cells were scraped and lysed in the presence of ice-
cold Laemmli buffer/protease inhibitor cocktail. An equal
amount of protein from each sample was loaded per lane, sep-
arated by SDS-PAGE, and transferred onto a nitrocellulose
membrane. Proteins were probed with specific antibodies in
PBS/0.2% Tween 20, or TBST in case of further detection of
phosphoproteins. Secondary antibodies conjugated to horserad-
ish peroxidase and Western Lighting Chemiluminescence Re-
agent Plus (Perkin-Elmer) were used to develop images.
Analysis of Activation of FAK, Src, PKB/cAkt, ERK1/2,
and Phosphorylation of p130Cas
The serum-starved cells (12-16 h in DMEM) were detached
with 2 mmol/L of EDTA, and subsequently resuspended in
DMEM/10% fetal bovine serum, or endothelial medium condi-
tioned by HUVEC for 2 d. Cell suspension was plated onto
dishes preabsorbed with Matrigel (20 μg/mL) for different
lengths of time. The cells were scraped into Laemmli sample
buffer supplemented with 2 mmol/L of phenylmethylsulfonyl
fluoride, 10 μg/mL of aprotinin, 10 μg/mL of leupeptin,
100 μmol/L of Na3VO4, 10 mmol/L of NaF, and 10 mmol/L
of Na3P4O7. Cellular proteins were resolved in 10% SDS-
PAGE, transferred to the nitrocellulose membrane, and probed
with the appropriate phosphospecific antibody.
Xenograft Experiments
Female athymic nude Foxn1 nu/nu mice at 6 wk of age were
purchased from Harlan, Italy. Mice were injected subcutane-
ously (above the hind leg) with 5 × 106 cells resuspended in
150 μL of HBSS (Invitrogen) per mouse. Six to 10 animals
per group were used in the experiments. Tumor growth was
monitored every other day and tumor volume was measured
with a Caliper instrument. Tumor volume (V) was calculated
by the “ellipsoid” formula: V = a × b × [(a + b) / 2] × π/6,
where a represents the minimum and b the maximum tumor
diameter. Tumors were fixed in 10% buffered formalin and pro-
cessed for histologic and immunohistochemical analyses. All
experiments were done in accordance with institutional and na-
tional animal research guidelines.
Immunohistochemistry
Antibodies to (a) CD151 (mouse anti-human, dilution 1:50),
(b) Ki-67 (rabbit anti-human, dilution 1:25), (c) F4/80 antigen
(rat anti-mouse, dilution 1:180), (d) FGF2 (rabbit anti-human,
dilution 1:50), (e) VEGF (mouse anti-human, dilution 1:200),
and (f) biotinylated L. esculentum lectin (dilution 1:50) were
used. After antigen retrieval, immunostaining of paraffin sec-
tions was done using a standard avidin-biotin-peroxidase com-
plex method. The sections counterstained with hematoxylin
were analyzed and images captured using the Olympus DP70
camera and the Olympus DP-Soft software (Japan). Tumor vas-
cularization was assessed using the Chalkley method (49). The
“hotspots” were at low (40×) magnification in three distinct
areas: (a) superficial (subcutaneous); (b) central (adjacent to ne-
crotic areas), and (c) close to the deep margin of the tumor. The
number of vessels (no. [CD151(−)] = 9; no. [CD151(+)] = 9)
was counted in nine high-power (400×) fields corresponding to
0.0625 mm2 from regions a to c. The numbers represent the
average from nine counts.
Proliferative Index in Tumor Sections
For each tissue sample, immunostaining with antibody to
Ki-67 was assessed by two independent observers. Only nuclear
immunoreactivity was considered positive. Initially, the entire
section was assessed at low magnification (40×) and three dis-
tinct regions of cell proliferation were identified: (a) superficial
(subcutaneous), (b) central (adjacent to necrotic areas), and (c)
close to the deep margin of the tumor. The number of Ki-67–
immunopositive cells in each sample (no. [CD151(−)] = 9;
no. [CD151(+) = 9]) was counted in nine high-power (400×)
fields from proliferation regions a to c (∼1,000 cells/section).
The mean ± SE were calculated and statistical analyses were
carried out by the unpaired t test using a GraphPad Prism 3.2
program (GraphPad Software).
Analysis of CD151 Immunohistochemical Expression in
Clinical Samples
Fifty-six specimens of primary invasive ductal carcinoma
(patients treated between 1998 and 2001) were obtained from
the archives of the Department of Oncology of Copernicus
Memorial Hospital (Lodz, Poland) following the local ethics
regulations. The disease was staged according to the tumor-
node-metastasis system and samples histologically graded
using the Nottingham Criteria. Pathologic analysis and surgical
evaluation confirmed the tissue diagnosis and the clinical stage
of disease. Follow-up period was defined as the time from
surgery to the last observation for censored cases or death
for complete observations. Five-micrometer formalin-fixed,
paraffin-embedded sections were processed for routine histolo-
gy and immunohistochemistry for ER (dilution 1:35; Dako, PL)
and CD151 (dilution 1:50; Novocastra). Immunostaining was
done after antigen retrieval by microwaving the sections for
8 min in citrate buffer (pH 6.0) and using the EnVision kit
(Dako, PL) according to the protocols of the manufacturer.
Assessment of CD151 immunoreactivity was as follows: (a)
negative—no staining or uniform membrane positivity in
<10% of the tumor cells; (b) positive—a weak to strong com-
plete membrane staining observed in >10% of the tumor cells.
Scoring for ER nuclear expression was done using the method
described by McCarty et al. (50). Tumors were considered pos-
itive for ER with a Histo-score of ≥100.
Statistical analysis. Overall survival was calculated from the
date of surgery to the date of death, or the last follow-up, as
recommended by the Kaplan-Meier method. Differences in
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survival distributions were compared using log rank test. Data
for patients who died from causes other than breast cancer were
censored at the time of death. Univariate analyses of overall
survival were done using the Cox proportional hazards regres-
sion model. Pearson's χ2 test was used to assess the associa-
tions between CD151 expression and clinicopathologic
variables. The results were considered statistically significant
when two-sided P values were <0.050. The analyses were done
using the StatsDirect software (StatsDirect, Ltd.).
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